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Oh, The Places You'll Go:
The Implications of Current
Patent Law on Embryonic
Stem Cell Research
Oh. the Places You'll Go!
Congratulations!
Today is your day.
You're off to Great Places!
You're off and away!
You have brains in your head.
You have feet in your shoes
You can steer yourself
any direction you choose.
You're on your own. And you know what you know.
And YOU are the guy who'll decide where to go.
OH!
THE PLACES YOU'LL GO!
You'll get mixed up, of course,
as you already know.
You'll get mixed up
with many strange birds as you go.
So be sure when you step.
Step with care and great tact
and remember that Life's
a Great Balancing Act...
And will you succeed?
Yes! You will, indeed!
(98 and 3 / 4 percent guaranteed.)
-Dr. Seuss*
* DR. SEUSS, OH, THE PLACES YOU'LL Go 1-48 (1990).
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I. INTRODUCTION
The United States Constitution provides that patents are to be granted to
"[p]romote the Progress of Science and useful Arts, by securing for limited
times to Authors and Inventors the exclusive Right to their respective
Writings and Discoveries."' This constitutional basis for the protection of
intellectual property rights provides a strong reason why the unwavering
need for intellectual property security is of such significance in the United
States today.
In the United States, a patent may be granted for those things that are the
result of "human ingenuity."2 Nevertheless, recent developments in the field
of biotechnology have highlighted the significance and ramifications of
patent protection and thereby have created great controversy as to what
exactly is "human ingenuity." Indeed, biotechnology carries with itself
enormous social, academic, and commercial consequences.3 Therefore,
granting a monopoly right, such as that which takes place when a patent is
awarded, places an extremely significant power in the hands of one or a few
people. A predominate example of this overwhelming power is currently
being experienced in the field of embryonic stem cell research, where a
single patent that protects a method of isolating embryonic stem cells, as
well as the cells themselves, has created great controversy.4
This Comment will outline the various aspects of current United States
patent law that inevitably impact the scope of the research performed on and
pertaining to embryonic stem cells. Many of these implications are currently
being felt in the biotechnology industry. However, the majority of these
ramifications and the extent of the impact are yet to be experienced. Part II
of this Comment will focus on the general requirements set forth by United
States patent law. Parts III and IV respectively, will address the scope of
embryonic stem cell research and the United States governmental impact.
Part V explains the implication of current patent laws on embryonic stem
cell research. Finally, Parts VI and VII focus on the potential future of
embryonic stem cell research and various considerations and
recommendations that should be noted as scientific advances in the field
continue to be made. Thus, this Comment will describe and analyze the
1. U.S. CONST. art. I, §8, cl. 8.
2. Diamond v. Chakrabarty, 447 U.S. 303, 303 (1980).
3. Byron V. Olsen, The Biotechnology Balancing Act: Patents for Gene Fragments, and
Licensing the "UsefulArts," 7 ALB. L.J. ScI. & TECH. 295, 298 (1997) (noting that granting patents
on gene fragments may actually hinder advancements in biotechnology).
4. Sheryl Cay Stolberg, Patent on Human Stem Cell Puts U.S. Officials in Bind, N.Y. TIMES,
Aug. 17, 2001, at Al.
state of the law and its many possible implications on embryonic stem cell
research while elucidating areas of discrepancies and inconsistencies in the
legal structure that impact an area of technology that will inevitably affect
everyone on a global and personal level.
II. GENERAL PATENT LAW
A. The Basic Premises for Granting a Patent
A United States patent is a grant from the government to an inventor of
the right to exclude others from making, using, or selling the inventor's
invention.' As a result, a patent permits controlled access to, and income
from, an invention's commercial, therapeutic, and/or scientific value.
Generally, there are three types of patents: design patents, plant patents, and
utility patents.6
A plant patent provides property protection to "any person who has
invented or discovered and asexually reproduced [a] new variety of plant"
that is not a tuber-propagated plant7 or one that is found in an uncultivated
state.8 Notably, just as it is possible to obtain patent protection for the
modification of bacteria, a plant patent may be granted for the modification
of plant cells. 9 However, when dealing with the current controversies
surrounding the area of biotechnology, plant patents are usually of little
significance.
A design patent is directed at protecting the overall appearance of an
invention, such as how the invention looks.'0 An inventor may be granted a
design patent for a new, original, and ornamental design for an article of
manufacture."' Because a design patent is limited to protecting the unique
design of various objects, it is seldom used in the field of biotechnology.12
A utility patent is the type that is granted most frequently in the field of
biotechnology. Generally, utility patents protect the structure and/or
5. BLACK'S LAW DICTIONARY 1125 (7thed. 1999).
6. Thomas G. Field, Jr., Brief Survey of Intellectual Property, 31 IDEA 85, 91-92 (1990).
7. Tubers are the underground stems on certain plants that are complete with nodes and axillary
buds, otherwise known as eyes. The propagation of tubers may occur by either planting the entire
tuber or cutting the tuber into pieces. Dewayne Ingram, Landscape Plant Propagation Workbook:
Unit IV. Propagation by Division, University of Florida, Institute of Food & Agricultural Sciences,
at http://www.edis.ifas.ufl.edu/BODY MG361 (last visited May 7, 2002).
8. Introduction to Understanding Patents, at http://www.lib.umich.edu/ummu/pattm/whatis.
html#plant (2001).
9. Ex parte Hibberd, 227 U.S.P.Q. 443, 444 (PTO Bd. of Patent Appeals and
Interferences 1985).
10. 35 U.S.C. § 171 (2002).
11. Id.
12. Olsen, supra note 3, at 311.
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function of the invention, such as how it works or how it is used, and is
normally sought when an inventor seeks protection over how the invention
operates. 13  A utility patent can be issued to any person for a process,
machine, manufactured article, composition of matter, or any new and useful
improvement to the aforementioned types of inventions.' 4  Thus, both a
product itself and the process by which the product is made may be
patentable with a utility patent. s
In most cases, inventors pursue the protection offered by a utility patent
because protecting the structure and/or function of the invention is
preferable to protecting the ornamental design of the invention.' 6 However,
where a meaningful utility patent may not be available, or if the appearance
of an invention is more important than its structure and/or function, design
patent protection may be the best option. There are also those situations
where an inventor feels that both the structure and/or function and the
appearance are important, and in such instances, both utility and design
patents may be sought for the same invention. Notably, when considering
patent protection for biotechnology, most applications are for utility
patents.17
B. Patent Law Requirements
A patent serves to protect that which is novel, unique, and useful. There
are four statutory requirements that must be satisfied before a patent can be
issued. That which is sought to be patented must fall within the class of
those things that are patentable, demonstrate some utility, be non-obvious to
a practitioner in the relevant field, and provide adequate disclosure.'
1. Patentability and Utility - § 101
Section 101 of the Patent Act' 9 provides that patent protection may be
obtained for "any new and useful process, machine, manufacture, or
13. 35 U.S.C. § 101 (2002); see also 35 U.S.C. § 151 (2001) (explaining general issues in
determining patentability).
14. Field, supra note 6, at 91.
15. Id.
16. See, e.g., Olsen, supra note 3, at 311.
17. See id.; see also John K. Flanagan, Gene Therapy and Patents, 80 J. PAT. & TRADEMARK
OFF. Soc'Y 739, 746 (1998) (noting that most of the patents granted in the field of gene therapy have
been utility patents in the form of process claims).
18. 35 U.S.C. §§ 101-104 (2002).
19. The Patent Act refers generally to Sections 1-376 of Title 35 of the United States Code.
Unless otherwise noted, all sections referred to pertain to the Patent Act.
composition of matter, or any new and useful improvement thereof."20 This
basic utility requirement demands a showing that the invention has some
practical application or use, but does not require that the invention be more
useful than an existing product or process.2' In practice, a lack of utility
rarely serves as a bar to the grant of a patent.
22
2. Novelty - § 102
To be patentable, an invention must also be novel. As such, Section 102
of the Patent Act generally provides that the invention cannot have been in
the hands of others and cannot have been disclosed, whether through
presentation or publication, to the public prior to the patent application. 23 A
publication by the inventor will not prevent the satisfaction of the novelty
requirement as long as the patent application is filed within one year from
the time of the publication.24
3. Non-Obviousness - § 103
Section 103 provides that differences between the invention and the
prior art must not be such that the prior art and "the subject matter as a
whole would have been obvious at the time the invention was made to a
person having ordinary skill in the art.,2 5  In determining whether an
invention is non-obvious, courts will look to secondary considerations as
indicia of non-obviousness. 26  Such secondary considerations include
evidence of commercial success, a basic need for the invention, and the
failure of others to develop the invention previously.
27
4. Disclosure - § 112
In exchange for the grant of the monopoly right associated with a patent,
an inventor must provide sufficient disclosure of the invention to the
public.28 Section 112 provides that a sufficient disclosure is that disclosure
of the invention, which would allow one skilled in the art to practice the
20. 35 U.S.C. § 101 (2002).
21. Id.
22. Flanagan, supra note 17, at 749-50 (explaining that "[t]he utility requirement generally does
not pose much difficulty for applicants in any field of invention.").
23. 35 U.S.C. § 102 (2002).
24. Id.
25. 35 U.S.C § 103 (2002).
26. See, e.g., Electro Scientific Indus., Inc. v. Gen. Scanning, Inc., 247 F.3d 1341 (Fed. Cir.
2001).
27. Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966).
28. 35 U.S.C. § 112 (2002).
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invention. z9  Generally, this disclosure requirement has two primary
objectives: 1) it ensures that the public will receive the complete benefit of
the invention when the patent term expires and, 2) it allows the Patent and
Trademark Office ("PTO") to determine that the patent applicant has truly
"developed an operative and useful embodiment of the invention., 30 Indeed,
the two functions served by the disclosure requirement "parallel[ ] scientific
norms by calling upon patent applicants, like publishing scientists, to
dedicate their inventions to the public ... [and] to supply sufficient
information and materials to demonstrate to a knowledgeable audience that
they have in fact achieved what they claim."31
C. Patents and Biotechnology
As modem biotechnology progresses, it is becoming more and more
evident that the same human creativity and ingenuity that gave rise to
inorganic discoveries has made significant advances in the biological
sciences possible.3 2 Therefore, "it is as logical to issue patents for work on
the truly novel and beneficial creations derived from the life sciences, as it is
to issue patents for inventions in the areas of computer science or
metallurgy. 33
Additionally, it is important to note that all patents, and in particular,
patents based on biotechnology, are to be evaluated within the appropriate
time frame. That is, although an invention to be patented may have obvious
potential to support an even greater invention or scientific advancement, its
novel, unique, and useful characteristics should be assessed based on the
state of the art at the time of the invention.34 In fact, the purpose of granting
"[p]atents [is to] encourage the dissemination of information about new
inventions, thus permitting competitors to build upon or develop improved
versions of patented inventions."35 Therefore, in a most basic sense, the
patenting of discoveries in biotechnology is essentially aimed at promoting
29. Id.
30. Rebecca S. Eisenberg, Proprietary Rights and the Norms of Science in Biotechnology
Research, 97 YALE L.J. 177, 207 (1987).
31. Id. at 207-08.
32. Olsen, supra note 3, at 317.
33. Id.
34. Lawrence M. Sung, Stranger in a Strange Land: Biotechnology and the Federal Circuit, 2
WASH. U. J.L. & POL'Y 167, 197 (2000).
35. Jay P. Kesan & Marc Banick, Administrative Law Issues: Patents as Incomplete Contracts:
Aligning Incentives for R&D Investments With Incentives to Disclose Prior Art, 2 WASH. U. J.L. &
POL'Y 23, 23 (2000).
the spread of these technologies to enhance further scientific advancements.
There is, nevertheless, a strong belief that patent laws should follow
historical guidelines to the extent that "[c]ertain things and objects
considered important or central to life or to the fundamental tenets of
society," should not be subject to the same rights as private property. 36 A
primary reason for this position is based on the historical goal of making
"such things available to all citizens and in some cases to humanity at
large."
37
D. Relevant Cases and Guidelines
In a decision that significantly impacted the property protection
available to stem cell innovations, the Court in Diamond v. Chakrabarty38
upheld a theory that human-manipulated life is patentable.39 With the
passing of over two decades since this decision, the rationale set forth by the
Court has been applied in the granting of patents on gene sequences, °
viruses, embryos, fetuses,41 embryonic stem cells, and even on a human-
engineered mouse. In addition to this decision, however, the patenting of
stem cell discoveries also follows the basic patentability guidelines.
1. Patentable Subject Matter and Utility
While the laws of nature, physical phenomena, and abstract ideas have
been held to be unpatentable, when patenting a biological discovery, the
PTO continues to follow the guidelines set forth in Graham v. John Deere
43
which noted that "ingenuity should receive a liberal encouragement." 44 As
such, applicants have been able to satisfy the patentable subject matter and
utility requirements under the theory that the patentee "has produced a new
[object] with markedly different characteristics from any found in nature and
one having the potential for significant utility.... [h]is discovery is not
36. Kojo YelPaala, Owning the Secret of Life: Biotechnology and Property Rights Revisited, 32
MCGEORGE L. REV. 111, 136 (2000).
37. Id.
38. 447 U.S. 303 (1980).
39. Id. at 310 (reasoning that "the patentee produced a new bacterium with markedly different
characteristics from any found in nature and one having the potential for significant utility. His
discovery is not nature's handiwork, but his own; accordingly it is patentable subject matter under §
101.").
40. Olsen, supra note 3, at 319.
41. Adam L. Penenberg, U.S. Patent Law Can't Cope With Human Clones, at http://www.wired.
con/news/politics/0,1283,2292,00.html (1997).
42. L.J. Deftos, Patenting Life: The Harvard Mouse That Has Not Roared, THE SCIENTIST, Nov.
27, 2000, at 6.
43. Graham v. John Deere Co., 383 U.S. 1 (1966).
44. Id. at7-10 (internal citations omitted).
560
[Vol. 30: 553, 2003] Oh The Places You 'll Go
PEPPERDINE LAW REVIEW
nature's handiwork, but his own; accordingly it is patentable subject matter
under Section 101."
5
Early interpretations of the utility standard only mandated that "the
invention should not be frivolous or injurious to the well-being, good policy,
or sound morals of society.'' 46 This standard, however, was narrowed when
the United States Supreme Court in Brenner v. Manson47 held that "until a
process is refined and developed [so that] specific benefit exists in currently
available form there is insufficient justification for permitting an applicant to
engross what may prove to be a broad field.'1 8 Nevertheless, the PTO has
recognized that it does not want to restrict the biotechnology field by making
the utility threshold too high, because in the eyes of the PTO, this would
unnecessarily burden this leading-edge industry. 9
Therefore, to address the ever-changing world of biotechnology, the
PTO did revisit the Utility Examination Guidelines on January 5, 2001. 50
The new guidelines prescribe that a claimed invention either have a well-
established utility or assert "a specific, substantial, and credible utility."51
This language is essentially adopted from the 1999 Revised Interim Utility
Examination Guidelines, which were a change to those prescribed in 1995,
in that they required a specific, not a substantial utility. 2
The "heightened standard was based on the PTO's adoption of the
United States Supreme Court's position in Brenner v. Manson that a patent
is not given as a reward for the search of an invention's utility but, rather, a
reward for actually discovering that utility."53 Some believe that the new
45. Chakrabarty, 447 U.S. at 309-10 (citing Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S.
127 (1948)).
46. Lowell v. Lewis, 15 F. Cas. 1018, 1019 (C.C.D. Mass. 1817).
47. Brenner v. Manson, 383 U.S. 519 (1966).
48. Id. at 534-35 (holding that a compound with only hypothetical utilities does not satisfy the
utility requirement of§ 101).
49. Michael Lane, Invention or Contrivance? Biotechnology, Intellectual Property Rights and
Regulation, Convention on Biological Diversity, at http://www.acephale.org/bio-safety/IoC-
indx.htm (Nov. 1995).
50. Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001).
51. Id. at 1093 (reasoning that a patent application for a steroid compound was rejected for
failure to state a substantial utility).
52. See Revised Interim Utility Examination Guidelines, 64 Fed. Reg. 7144 (Dec. 21, 1999).
53. Comment, The Fate of Gene Patents Under the New Utility Guidelines, 2001 DUKE L. &
TECH. REV. 0008, available at http://www.law.duke.edu/joumals/dltr/articles/2001dltrOO08.html
(citing Brenner v. Manson, 383 U.S. 519, 536 (1966) (stating that "a patent is not a hunting license.
It is not a reward for the search but compensation for its successful conclusion.")); see also Mark
Jagels, Dr. Moreau Has Left the Island: Dealing With Human-Animal Patents in the 21" Century, 23
T. JEFFERSON L. REV. 115, 137 (2000) (explaining that the holding in Brenner essentially required
"that the invention must be shown to have a definite, immediate and demonstrable utility.").
guidelines reflect the PTO's perception of "the genetically altered state of
Utility. '54 These new guidelines prescribe the following:
If a patent application discloses only nucleic acid molecular
structure for a newly discovered gene, and no utility for the claimed
isolated gene, the claimed invention is not patentable. However,
when the inventor also discloses how to use the purified gene
isolated from its natural state, the application satisfies the "utility"
requirement."
It is this relatively broad concept of utility that has permitted the
patenting of embryonic stem cells." However, while some perceive these
revised utility guidelines of the PTO to be broad and standardized, 57 many in
the biotech community contend that the utility guidelines actually are too
narrow and thereby may in fact operate as a deterrent to research."
E. Obviousness
That which constitutes obviousness in biotech inventions has been
outlined in several court cases. The Federal Circuit Court in In re DeueP9
reversed a decision of the PTO Board of Patent Appeals ("the Board") and
held that the patent claims to a process of isolating and making
deoxyribonucleic acid ("DNA") molecules were not obvious.6 ° However, in
In re Mayne,6 claims to proteins comprising methionine connected to the
enterokinase cleavage site and coupled to human Growth Hormone ("hGH")
or bovine Growth Hormone ("bGH") were rendered obvious because the
prior art taught the use of fusion proteins and identified cleavage sites for
enterokinase. 62  Recent decisions by the Board have applied this logic in
noting that "'[w]hen obviousness is based on a particular prior art reference,
there must be a showing of a suggestion or motivation to modify the
54. Albert L. Jacobs & Jeffrey A. Glazer, The PTO Redefines Genomic Ingenuity, New York
Law Journal, available at http://www.gtlaw.com/pub/articles/2001/jacobsa0la.htm (March 12,
2001).
55. Id.
56. See infr'a, notes 92-121 and accompanying text.
57. See Lane, supra note 49.
58. Timothy A. Worrall, The 2001 PTO Utility Examination Guidelines and DNA Patents, 16
BERKELEY TECH. L.J. 123, 135 (2001) (noting that the 2001 Utility Guidelines could potentially
restrict advances in DNA research).
59. 51 F.3d 1552 (Fed. Cir. 1995).
60, Id. The court determined that DNA and complimentary deoxyribonucleic acid ("cDNA")
molecules encoding proteins that stimulated cell division were not obvious in light of a prior art
reference teaching a method of gene cloning together with a reference disclosing a partial amino acid
sequence for a protein that stimulated cell division. Id.
61. 104 F.3d 1339 (Fed. Cir. 1997).
62. Id. at 1343-44.
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teachings of that reference."'' 63 Additionally, a "reasonable expectation of
success" is not the sole consideration in an obviousness determination; it is
also necessary to consider whether the prior art would have suggested the
proposed modification.64
F. Enablement
The court in Enzo Biochem, Inc. v. Calgene, Inc.65 held that claims of
antisense nucleic acids to regulate gene expression in eukaryotic and
prokaryotic cells, when the application only provided examples for
prokaryotic cells, failed to meet the enablement requirement. 66 Additionally,
in Genentech, Inc. v. Novo Nordisk,67 claims to cleavable fusion expression
failed to meet the enablement requirement because the patent failed to
provide any specific cleavable conjugate proteins or any reaction conditions
under which cleavable fusion expression would work.68 Thus, in the biotech
community, it is generally believed that "courts have applied a fairly
stringent enablement standard to ... claims because of the perceived
unpredictability of biotechnology.', 69
III. STEM CELL RESEARCH
A. Historical Basis
The term "stem cell" is typically used to refer to cells within an adult
organism that renew tissue.70 More specifically, a stem cell is a type of cell
that has special abilities to renew itself and form different specialized cell
types.7' Stem cells are of various types, 72 including the most recent to be
63. Ex Porte Stephan J.W. Platzer, No. 1997-3334, 2001 WL 1057504, at *2A (Bd. Pat. App. &
Interf. 2001) (citing B.F. Goodrich Co. v. Aircraft Braking Sys. Corp., 72 F.3d 1577, 1582 (Fed.
Cir. 1996)).
64. Id.
65. 188 F.3d 1362 (Fed. Cir. 1999).
66. Id. at 1362-63.
67. 108 F.3d 1361 (Fed. Cir. 1997).
68. Id. at 1367.
69. Eric Guttag, Unpredictability - The Two-Edged Sword in Patenting Biotechnology, at
http://tenonline.org/art/ip1/0003.html (2001).
70. National Bioethics Advisory Commission, Ethical Issues in Human Stein Cell Research:
Executive Summary, at http://www.bioethics.georgetown.edu/ubac/execsumm.pdf (Sept. 1999).
71. Nat'l Inst. of Health, Stem Cells: Scientific Progress and Future Research Directions, U.S.
Dep't of Health and Human Services, ES-1 (2001), available at http://www.nih.gov/news/stemcell/
scireport.htm.
discovered, embryonic stem cells, which were first isolated at Johns Hopkins
University School of Medicine in 1997."3 Embryonic stem cells differ from
adult stem cells in that they are found naturally in the early stage of
embryonic development.74 Generally, embryonic stem cells can be located
"after the egg is fertilized and has begun dividing, but before the mass of
cells attaches itself to the wall of the uterus. 75
One of the most valuable features of embryonic stem cells is that they
are pluripotent or, put another way, have the ability to divide and thereby
give rise to differentiated cell types from all three germ layers of the
embryo, the endoderm,76 the mesoderm,77 and the ectoderm.78 More simply
stated, unlike other human cells, such as heart cells or skin cells [which] are
committed to conduct a specific function, a stem cell is uncommitted and
remains uncommitted, until it receives a signal to develop into a specialized
cell, and maintains the ability to form any kind of adult cell or adult cell
precursor.79  As a result, embryonic stem cells present great potential for
72. Nelle S. Paegel, Use of Stem Cells in Biotechnological Research, 22 WHITTER L. REV.
1183, 1185 (2001) (noting that "[w]hile human bone marrow stem cells have been used for research
for many years, embryo stem cells have not.").
73. Ricki Lewis, Embryonic Stem Cells Debut Amid Little Media Attention, THE SCIENTIST,
Sept. 29, 1997, at I.
74. See id.
75. David Tenenbaum, Finally, Generic Human Cells Discovered, at http://whyfiles.org/shorties/
stem_cell.html (Nov. 20, 1998); see also University of Wisconsin, Embryonic Stem Cell Fact Sheet,
Office of News and Public Affairs (Nov. 5, 1998), available at http://www.news.wisc.edu/thisweek/
Research/BioiY98/facts.html (noting that human embryonic stem cells can be derived from in vitro
fertilized embryos that are less than one week old).
76. Meta Library, at http://www.meta-library.net/biogloss/endrm-body.html (last visited Oct. 29,
2002) (stating that "The endoderm is the innermost of the germ layers of an embryo and is the source
of the epithelium of the digestive tract and its derivatives.").
77. Meta Library, at http://www.meta-library.net/gengloss/index-frame.html (last visited Oct. 28,
2002) (stating that the mesoderm is the middle of the three primary germ layers of an embryo, which
forms many of the bodily tissues and structures including bone, muscle, connective tissue, and skin).
78. Id. The ectoderm is the outermost of the three primary layers of an embryo and is
responsible for producing "the nervous system, the epidermis and epidermal derivatives, as well as
the lining of various body cavities such as the mouth." Id.; see also Jason H. Casell, Lengthening the
Stem: Allowing Federally Funded Researchers to Derive Human Pluripotent Stem Cells From
Embryos, 34 U. MICH. J.L. REFORM 547, 551 (2001) (explaining that stem cells, which potentially
can give rise to all cells in the body, hold promise for treating almost all, if not all, diseases); see
also Nat'l Inst. of Health, Stem Cells. Scientific Progress and Future Research Directions, Dep't of
Health and Human Services, ES-I (2001), available at http://www.nih.gov/news/stemcell/scireport.
htm.
79. Meta Library, at http://www.meta-library.net/gengloss/index-frame.html (last visited Oct. 28,
2002); see also J.W. McDonald, et al., Transplanted Embryonic Stem Cells Survive, Differentiate
and Promote Recovery in Injured Rat Spinal Cord, NATURE MEDICINE, Dec. 1999, at 1410-12; see
also Sharon M. Parker, Bringing the "Gospel of Life" to American Jurisprudence: A Religious,
Ethical, and Philosophical Critique of Federal Funding for Embryonic Stem Cell Research, 17 J.
CONTEMP. HEALTH L. & POL'Y 771, 777 (2001).
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therapeutic treatments and possible cures for many life-threatening
diseases.8 °
Embryonic stem cells can be formed.by different methods. Most of
these methods have been subject to great debate as the process involves the
manipulation of human embryos "to provide a source of embryonic stem
cells which can be isolated and extracted from the inside layer or the inner
cell mass of a pre-embryo (known as a blastocyst)." 8' One method involves
the extraction of the stem cells from human embryos.82 The human embryos
used to harvest the stem cells may be those that were created by in vitro
fertilization for couples who are attempting to overcome infertility.83 The
primary manner by which these embryos become available to scientists for
manipulation is when they are donated for research purposes by couples that
no longer have plans to use the embryos as a means to deal with their
personal infertility issues.8' Human fetal tissue following an elective
abortion may also provide access to the embryonic germ cells that can be
manipulated to produce embryonic stem cells. 85 Researchers may also
obtain access to human embryos by acquiring these embryos created by in
vitro fertilization using gametes donated for the sole purpose of facilitating
research or by human or hybrid embryos generated asexually. 86 This is a
process similar to the one used to clone the well-known sheep "Dolly" in
Edinburgh Scotland in 1997.87
80. Nat'l Inst. of Health, Stem Cells: Scientific Progress and Future Research Directions, Dep't
of Health and Human Services, ES-I (2001), available at http://www.nih.gov/news/stemcell/
scireport.htm.
81. Lori P. Knowles, Science Policy and the Law: Reproductive and Therapeutic Cloning, 4
N.Y.U. J. LEGIS. & PUB. POL'Y 13, 14 (2000); see also Paegel, supra note 72, at 1187-88 (noting
that the role of scientists is to find a way to stimulate stem cells into differentiating into specific cells
in hopes that it is possible to treat stem cells in "a way as to effectuate this 'trigger' mechanism,
perhaps for example, through the growing medium. Assuredly, if there is a way in which to
accomplish this feat of engineering, these highly talented scientists will figure it out, given sufficient
time and resources.").
82. The method of acquiring embryonic stem cells is of great ethical debate. That is, the legal
status of a human embryo is often highlighted, particularly when determining whether or not federal
funds should be allocated to stem cell research, which requires the destruction of human embryos.
Parker, supra note 79, at 787-89; see also National Legal Center for the Mentally Dependent &
Disabled, Inc., On Human Embryos and Medical Research: An Appeal for Ethically Responsible
Science and Public Policy, 16 ISSUES IN LAW & MEDICINE 261, 265 (2001).
83. Parker, supra note 79, at 783.
84. Id.
85. Id.
86. National Bioethics Advisory Commission, Ethical Issues in Stem Cell Research: Executive
Summary, at http://bioethics.georgetown.edu/hbac/exec.summ.pdf (Sept. 1999)
87. Knowles, supra note 81, at 14-15. The process used to clone "Dolly" is referred to as
Somatic Cell Nuclear Transfer. The technique, which has been subject to intense international
B. Stem Cell Potential
There is a general belief in the scientific community that various
embryonic stem cell stocks of different immunotypes could be used for the
replacement of distinct dysfunctional cell types in the body.88 It is further
believed that this could be accomplished without the need for cross matching
a donor or suppressing the immune system. 89 As a result, one of the greatest
outcomes of embryonic stem cell research could be the treatment of diseases
that affect various isolated cell types such as juvenile onset diabetes,
Alzheimer's disease, which affects brain cells, and Parkinson's disease,
which degrades nerve cells. 90 Furthermore, "failing hearts and other organs,
in theory, could be shored up by injecting healthy cells to replace damaged
or diseased cells." 9' Thus, embryonic stem cells are invaluable for their
potential use as an "unlimited quantit[y] of normal human cells of virtually
any tissue type" for use in drug screening.92
debate, involves the creation of embryos to provide a source of stem cells. Scientists believe that
these stem cells can then be cultured to produce cells or tissue that can be used as replacements for
tissue that has been destroyed or damaged by disease. Thus, the Somatic Cell Nuclear Transfer
process, which is often called therapeutic cloning, allows for the creation of stem cells and resultant
tissue cultures that are genetically identical to that of the donor/recipient from which the stem cells
were harvested, thereby reducing or eliminating the incidence of rejection. See also Alexandra
Hawkins, Protecting Human Dignity and Individuality: The Need for Uniformity in International
Cloning Legislation, 14 TRANSNAT'L LAW 243, 268 (2001) (reasoning that despite a general belief
that United States laws could push stem cell research abroad, following the creation of "Dolly,"
"[n]umerous international organizations and many countries immediately sought to place restrictions
on the use of nuclear transfer and to ban any use of the procedure for human cloning."); see also
Paegel, supra note 72, at 1183-84.
88. Daniel McConchie & Linda Bevington, Stem Cell Research. A Constructive Way Forward,
The Center for Bioethics and Human Dignity (1999), available at http://www.bioethix.org/
newsletter/992/992mcc-bev.htm.
89. David Tenenbaum, Finally, Generic Human Cells Discovered, at http://whyfiles.org/shorties/
stem_cell.html (Nov. 20, 1998).
90. University of Wisconsin, Embryonic Stem Cell Fact Sheet, Office of News and Public
Affairs (Nov. 5, 1998), available at http://www.news.wisc.edu/thisweek/Reaserch/Bio/Y98/
facts.html; see also Parker, supra note 79, at 773; see also Stolberg, supra note 4, at Al (noting that
"[tiheoretically the cells can be coaxed in the laboratory to grow into any cell or tissue - insulin-
producing cells to use against diabetes, for example, or nerve cells that might treat Parkinson's
disease."); see also Knowles, supra note 81, at 15 (indicating that the use of therapeutic cloning
techniques could be used to create autologous embryonic stem cells that could be stimulated to
develop into skin for use in treating bum patients).
91. University of Wisconsin, Embryonic Stem Cell Fact Sheet, Office of News and Public
Affairs (Nov. 5, 1998), available at http://www.news.wisc.edu/thisweek/Research/Bio/Y98/
facts.html.
92. Eliot Marshal, A Versatile Cell Line Raises Scientific Hopes, Legal Questions, SCIENCE,
Nov. 6, 1998, at 1145-47 (internal quotations omitted); see also Paegel, supra note 9, at 1185
(indicating that stem cells have the potential to be grown artificially and thereby may be used to
replace tissues that are dead or damaged by diseases such as Parkinson's disease, Alzheimer's
disease, heart maladies, and stroke); see also Nat'l Inst. of Health, Stem Cells: Scientific Progress
and Future Research Directions, Dep't of Health and Human Services (2001) (noting that the full
extent to which embryonic stem cells will be instrumental in developing cell-based therapies to treat
disease remains unknown at the present time), available at http://www.nih.gov/news/stemcell/
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IV. UNITED STATES GOVERNMENTAL REGULATIONS OF STEM CELL
RESEARCH
A. 1999 Regulations
In 1999, a bill prohibiting the extraction of embryonic stem cells using
federal funds was passed and placed in the bylaws of the National Institutes
of Health ("NIH").93 The 1999 regulations further noted that embryonic
stem cells that were able to be isolated could only be multiplied ten to one
hundred times.94 A direct ramification of this multiplication restriction was
that many embryos would need to be destroyed for routine clinical testing
and experimentation.95 Furthermore, in light of these regulations, it
appeared that federal funds to support embryonic stem cell research were, by
all essential means, out of the question.96
B. 2001 Regulations of Stem Cell Research
In April 2001, Senator Arlen Specter (R-Pa.) introduced the Stem Cell
Research Act of 2001. 9' The proposed act is aimed at giving federally
funded researchers more freedom to work with embryonic stem cells and is
based on the premise that:
[W]e have a duty to accelerate medical research by allowing
researchers to utilize Federal funds to derive their own stem cells.
Human embryonic stem cell research holds such potential for
millions of Americans who are sick and in pain that we believe it is
wrong for us to prevent or delay our world-class scientists from
building on the progress that has been made. Our legislation creates
one narrow and specific source for Federal researchers to obtain
embryos for use in stem cell research: embryos which would
otherwise be discarded from in-vitro fertilization clinics, with the
scireport.html.
93. Nat'l Inst. of Health, Stem Cells: Scientific Progress and Future Research Directions, Dep't
of Health and Human Services (June 2001), available at http://www.nih.gov/news/stemcell/
scireport.html.
94. Id.
95. Id.
96. Natalie Larsen, Cultured Neural Stem Cells Reduce Symptoms in Model of Parkinson's
Disease, Nat'l Inst. of Health News Release (July 20, 1998), available at http://www.ninds.nih.gov/
newsand events/pressreleasestemcells 072098.htm?type=archived.
97. Casell, supra note 78, at 567.
expressed consent of the donating families. In addition, a provision
is included which requires that all Federally-funded research must
adhere to strict procedural and ethical guidelines to ensure that such
research is conducted in an ethical, sound manner. It is important to
note that as it stands today, embryonic stem cell research in the
private sector is not subject to Federal monitoring or ethical
requirements.98
This bill, which Senator Specter admitted would be controversial, laid
the foreground for what would be the first of many steps taken by the United
States federal government in response to embryonic stem cell innovations.99
Thus, in August 2001, United States President George W. Bush,
responding to the heightened public awareness of the ramifications of stem
cell research, approved the use of over $250 million in federal funding to
support existing stem cell lines.' 00 The decision, which was made after the
completion of an investigation by the National Bioethics Advisory
Commission on behalf of the NIH, further outlined that taxpayer money may
not be used to finance the creation of new stem cell lines in the United
States.'0 ' In light of these guidelines, President Bush's decision has been
criticized for its inconsistencies with the Federal Consolidated
Appropriations Act of 2000.102 The Consolidated Appropriations Act of
2000 provides in part:
None of the funds made available in this Act may be used for - - (1)
the creation of a human embryo or embryos for research purposes;
or (2) research in which human embryos are destroyed, discarded,
or knowingly subjected to risk of injury or death greater than that
allowed on fetuses in utero.... 103
The NIH, the governmental agency in charge of implementing President
Bush's new plan, 104 contends that the use of embryonic stem cells is not in
violation of the language in the budgets.'0 5 The use of federal funds for
embryonic research is available for limited circumstances, such as stem cell
research, through "a loophole in the law" which notes that embryos can be
used provided:
98. 147 CONG. REC. S3553 (daily ed. Apr. 5, 2001) (statement of Sen. Specter).
99. Casell, supra note 78, at 568.
100. Paegel, supra note 72, at 1183.
101. Id.
102. Id.
103. Id.
104. Stolberg, supra note 4, at Al.
105. Paegel, supra note 72, at 1184.
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(1) the cells used in NIH-funded research come from excess
embryos derived through in vitro fertilization at fertility clinics °6,
(2) the donors give informed consent to using their embryos for
research, (3) the donors donate the embryos, (4) no embryos are
created specifically for research purposes, (5) only private firms
harvest the cells, (6) the stem cells are not to be used to clone a
human being, and lastly, they cannot be combined with animal cells
to create a hybrid.107
The NIH, based on the investigations of the Department of Health and
Human Services, further justified the exemption of embryonic stem cell
research from the congressional ban on human embryo research in that "the
cells are not an embryo as defined by statute... since human embryonic
stem cells 'do not have the capacity to develop into a human being ....
Nevertheless, in questioning Bush's stem cell policy, a spokesman for the
American Association for the Advancement of Science has stated:
We need to know how many of the existing cell lines have been
derived in a manner that would meet or exceed the ethical standards
that the American public expects will be associated with such
research. Too often we have learned that procedures used in other
parts of the world in research with human subjects do not measure
up to the ethical standards that we embrace in this country.'09
These and other ramifications of the new embryonic stem cell policy
remain of optimal concern to the NIH." For instance, President Bush
indicated that there are allegedly over sixty stem cell lines currently existing
in the world and researchers are free to work with any of these lines."'
106. Teresa Wood, University of Florida: New Cell Research Guidelines Help University of
Florida Scientists Find Cures, U-WIRE, Aug. 30, 2000 (reasoning that the supply of embryos
federally supported to be used by embryonic stem cell researchers are those that are left over from
fertility treatment facilities, however, federal funds are specifically not permitted for these facilities),
available at 2000 WL 24490957.
107. Paegel, supra note 72, at 1184.
108. Id. at 1198 (noting that even if implanted into the womb of a human female, embryonic stem
cells are not to be considered embryos).
109. Ted Agres, Stem Cells: Steady Momentum Toward Funding, THE SCIENTIST, Sept. 17, 2001,
at 8.
110. Paegel, supra note 72, at 1220 (noting that the "[e]ase of embryo acquisition is integral to
researchers who need them.").
11. Agres, supra note 109, at 8 (explaining that ten organizations have said they have stem cell
lines that meet all of the criteria to qualify for federal funding under President Bush's new
guidelines).
However, it is important to note that while the government may dictate
which cell lines may receive the benefit of federal funding, the government
does not have control over whether researchers get access to these lines." 
2
And, while no real federal restraints exist on the scope of embryonic stem
cell research in the private sector, "private research is hindered by economic
constraints.""13 Thus, all of those involved in the development of stem cell
technologies are affected by the current state of property rights and general
legislation.
C. International Impact and Presence
Unlike the United States, other countries, such as the United Kingdom,
do not have as many restrictions on the use of human embryos in research."
14
In fact, in January of 2001, the United Kingdom passed a law making it legal
to create human embryos for the sole purpose of research." 5 Thus, scientists
in the United Kingdom currently may derive their own cell lines and
continue to do so until they get what they need."
16
Indeed, other nations, such as the United Kingdom, do not appear to fear
regulation, as does the United States. 1 7 That is, in the United States, "there
is a widespread belief that mere political discourse about the collective good
inevitably threatens individual conceptions of what is good. Americans tend
to believe that collective good is somehow oppressive.""' 8 Thus, the general
thought among the biological community is that the regulations that exist in
the United Kingdom are clear and predictable in comparison to those in the
United States.'' 9
112. Id.
113. Paegel, supra note 72, at 1189.
114. Stolberg, supra note 4, at Al; see also Paegel, supra note 72, at 1188-89 (reasoning that
while the government in the United States is lagging behind other countries in the race for stem cell
development, private companies are extremely diligent in working on the technology but are
constrained by a lack of funding and access to quality scientists such as those employed at the
National Institute of Health).
115. U.K. Embryonic Stem Cell Research Expansion Approved By The House of Lords, BLUE
SHEET, Jan 24, 2001 (documenting votes by both the House of Lords and the House of Commons to
allow the expansion), available at 2001 WL 7810876; see also Knowles, supra note 81, at 20-21
(noting that the United Kingdom, after first considering the consequences of assisted reproductive
technologies in the Warnock Report of 1984, adopted a broad regulatory framework that allows for
flexibility and adaptability when faced with new human embryological and fertilization
technologies).
116. U.K. Embryonic Stem Cell Research Expansion Approved By The House of Lords, BLUE
SHEET, Jan 24, 2001, available at 2001 WL 7810876.
117. Knowles, supra note 81, at 21.
118. ld. at 21-22 (noting that "the United States fails to discuss the larger scientific and societal
context relevant to cloning technologies.").
119. Arlene Judith Klotzko, Embryonic Victory: Americans Are Looking to Britain to get Them
Out of Bush's Stem Cell Morass, THE GUARDIAN, Aug. 20, 2001, at 19; see also Rebecca Hover,
Stem Cell Debate Worth Study, Even Adjustment (Aug. 22, 2001) (reasoning that there is
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One potentially adverse ramification of this industry sentiment is that in
the United Kingdom, and incidentally throughout the global scientific
community, there is a sense of satisfaction that the United States is creating
such complicated legal and regulatory burdens in the area of embryonic stem
cell research, that researchers in the United Kingdom and other countries
will obtain a sustainable competitive advantage over the United States in this
area. 20 Notably, this perspective could have an adverse impact not only on
the United States but the world's economy and society as a whole.
It is important to note that international applications of biotechnological
innovations augment the need for greater integration of scientific
experimentation, ethical discourse, and legislative responses. It can only be
beneficial to take note of the wisdom and experience of international
thinkers and policymakers on a bioethical issue of domestic import. "A
comparative international analysis can be useful in confirming society's
beliefs or in highlighting societal differences and responses. '  Thus, many
in the biotech field believe that the United States should be very attentive of
international developments in embryonic stem cell research because it not
only holds significant scientific potential, but political, social, and economic
possibility as well.
V. PATENT LAW IMPLICATIONS
A. Intellectual Property Protection of Embryonic Stem Cells
In 1998, Patent 6,200,806 ("'806") was granted to the University of
Wisconsin's Wisconsin Alumni Research Foundation ("WARF"). The '806
patent was the result of extensive experimentation by "Dr. James A.
Thomson, a developmental biologist at the University of Wisconsin, [who]
shook up the stem cell world by reporting that he had isolated human
embryonic stem cells.' ' 122  Dr. Thomson and his team of researchers
established five independent cell lines using fourteen blastocysts 23 that the
international belief that President Bush's stem cell "policy is so political that it must hinder the
practicalities of research."), at http://www.heraldnet.com/Stories/01/8/22/1425229l.cfm.
120. Rebecca Hover, Stem Cell Debate Worth Study, Even Adjustment (Aug. 22, 2001), at
http://www.heraldnet.com/Stories/0l/8/22/14252291.cfm.
121. Knowles, supra note 81, at 18.
122. Stolberg, supra note 4, at Al.
123. David Gardner, et al., A Prospective Randomized Trial of Blastocyst Culture and Transfer in
In- Vitro Fertilization, HUMAN REPRODUCTION, Dec. 1998, at 3434. A blastocyst, which is generally
formed in humans on the fifth day after fertilization, is an embryo that has developed to the stage
where it has two different cell types and a central fluid-filled cavity: the surface cells of the
University had obtained from surplus donated embryos. 124  The resulting
patent on the discovery was then assigned by Dr. Thomson to WARF, as is
customary practice at the University of Wisconsin.
25
The '806 patent covers a method of isolating stem cells as well as the
stem cells themselves. 2 6  That which is of particular intrigue to the
biotechnology community is that, as far as experts know, the '806 is the only
patent of its type in the entire world. 127 Notably, however, "[t]he patent is
valid only in this country," but WARF "has also applied for patents in
Europe."'
28
Through a private contract, WARF has granted rights to Geron
Corporation, a biotechnology company located in Menlo Park, Califomia.
129
Geron, incidentally, contributed over $1 million in 1995 to the research that
resulted in the stem cell line patented by WARF. 30 While this agreement
between WARF and Geron did not give Geron the complete rights to the
stem cell line,' 3' it did provide Geron with the rights to develop stem cells
into six different types, each of which are of great medical significance.
132
These six cell types include blood, liver, muscle, nerve, bone and pancreas
cells.'33
In its most basic sense, this agreement provides Geron with an almost
exclusive say over who eventually profits from the stem cell therapies.
134
blastocyst become the placenta, and the inner cells become the fetus. Id.
124. See University of Wisconsin, Embryonic Stem Cell Fact Sheet, Office of News and Public
Affairs (Nov. 5, 1998), available at http://www.news.wisc.edu/thisweek/Research/Bio/Y98/
facts. html.
125. Id. (noting that WARF had already obtained a patent on the primate embryonic stem cell,
after Dr. Thomson derived those cells from rhesus monkeys).
126. Id.
127. Id.
128. Id. (noting that "at least two biotechnology companies say their cell lines may fall outside
Wisconsin's claim and have applied for patents of their own in the United States and elsewhere).
129. ABC NEWS, A Powerful Patent (Aug. 18, 2001), available at http://www.abcnews.go.com/
sections/wntIDailyNews/wntstemcellsO 10818.html.
130. Id.; see also Jason Gertzen, Stem Cell Patents Put UW Agency in Spotlight, MILWAUKEE
JOURNAL SENTINEL, Aug. 26, 2001 (noting that when Dr. Thomson began attempting to isolate
human embryonic stem cells, he used private financial backing since federal regulations prohibited
the funding of research for human embryos).
131. See Stolberg, supra note 4, at Al (noting that according to WARF's managing director, Mr.
Carl Gulbrandsen, "[Geron] wanted all rights .... [w]e felt it was too much to expect a small
company to develop this technology fully, and giving them all rights would not be fair to them or the
public.").
132. Id.; see also Rebecca Hover, Stem Cell Debate Worth Study, Even Adjustment (Aug. 22,
2001) (explaining that "patent law is becoming a key concern for many scientists. Some fear that
prospects for practical new cures will be blocked by a combination of broad patents held [by WARF]
and a licensing agreement the foundation has with [Geron]."), at http://www.heraldnet.com/Stories/
01/8/22/14252291 .cfm.
133. Stolberg, supra note 4, at Al.
134. Id. (reasoning that Geron's rights, "coupled with the Wisconsin patent, might mean that
anyone seeking to develop commercial applications of stem cells in these six areas must negotiate
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Thus, agreements such as that between WARF and Geron, present
researchers with an overwhelming concern that they will not be able to gain
access to stem cell lines that are patented by private companies. 135 As a
result, there is a strong belief among researchers and businesses that
President Bush's recent financing guidelines, which disallow federal funding
to be used for the development of new lines, seriously hinders the chance of
a threat to the '806 patent monopoly. 136 In fact, many in the biotechnology
community contend that:
[t]he Bush compromise actually locks in the commercial advantage
of WARF and Geron by perpetuating the status quo. The inability
of federally-funded researchers to derive their own stem cell lines
will make it harder for them to figure out a derivation method that
would get around WARF's patent. Even more ominously, publicly
funded scientists will find it much harder to be doing the first class
science they should be doing. And making the discoveries they
could be making. 13
In addition to the controversy created by the very existence of the
Geron-WARF agreement, in August of 2001, WARF filed a lawsuit against
Geron. 138 The complaint by WARF alleged that Geron sought to extend its
commercial rights to another twelve derivative cell types. 3 9 It is generally
perceived that WARF took this action in an alleged attempt to limit Geron's
ability to work with other researchers. 140
Nevertheless, in order to promote the issues of access to the embryonic
stem cell lines, the University of Wisconsin has set up a non-profit
subsidiary, the WiCell Research Institute, to distribute the five embryonic
stem cell lines currently developed.' 41 Academic researchers who wish to
access the stem cell lines through WiCell Research are subject to a
"materials transfer and license agreement" and must pay the institute
$5000.142 In addition, the researchers must agree to certain restrictions such
with Geron first.").
135. Andrea Tortora, Research Rush: Cincinnati May be in the Perfect Position to Capitalize on
Bush's Embryonic Stem Cell Ruling, BUSINESS COURIER, Aug. 20, 2001.
136. See Stolberg, supra note 4, at Al.
137. Klotzko, supra note 119, at 19.
138. Id.
139. Id.
140. Id.
141. See Gertzen, supra note 130.
142. Id.
as not using the lines commercially.143 The ultimate effects of the actions
taken by the University of Wisconsin are that the university, and by
extension, Geron, have the ultimate control over the derivative cells. This
fact alone has led to the frustration of many scientists.144 For instance, one
prominent stem cell scientist has noted that he is indeed the ideal employee
of Geron: "[t]hey don't pay my salary, they don't pay my benefits, but
anything I discover they own.' 45 As a result, this scientist will not agree to
the terms of the agreement between WARF, WiCell, and Geron.1
46
B. Pressure on WARF and Geron
Despite the legal battle between the two, both WARF and Geron are
being pressed to provide access to the patented stem cell line because it is a
fundamental tool for stem cell research. 147 However, WARF and Geron are
very hesitant to provide this demanded access because each, individually and
collectively, wants to protect their legal rights to a discovery that could
potentially be worth millions of dollars, particularly to WARF researchers.1
48
In fact,
President Bush's decision may have strengthened the hands of the
Wisconsin group and Geron. By refusing to allow taxpayer money
to finance [the] creation of new cell lines in this country, Mr. Bush
reduced the chances that scientists would derive and patent cells
that might challenge Wisconsin's dominance in the field.'
49
Rebecca S. Eisenberg, an expert in biotechnology and patent law at the
University of Michigan, notes that "[w]hat constrains the monopoly power
of a patent holder is the prospect of new technology being developed that
will make it unnecessary to deal with them, . . . [t]he president's decision
limits that threat."' 150 Interestingly, the NIH, which is assigned to carry out
President Bush's plan, admits that:
143. Id. (noting that researchers who make a discovery using the patented stem cell lines may
publish the results or even obtain patents of their own without WARF's permission, but if seeking to
commercialize on the discovery, the researcher must first negotiate licensing terms with WARF and
possibly Geron).
144. See Stolberg, supra note 4, at Al.
145. Id. (internal quotations omitted).
146. Id.
147. Id.
148. Gertzen, supra note 130 (noting that WARF insists that it must strictly enforce its patents
because failure to do so could invalidate them).
149. Stolberg, supra note 4, at Al.
150. Id. (internal quotations omitted).
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Scientists upon making new discoveries often verify reported results
in different laboratories and under different conditions. Similarly,
they will often conduct experiments with different animal models
or, in the case, different cell lines. However, there have been very
few studies that compare various cell lines with each other. It may
be that one source proves better for certain applications, and a
different cell source proves better for others. 51
Indeed, this suggestion by the NIH promotes the antithesis of the effects
that current stem cell regulations, which are to be carried out by the NIH,
will most likely impose.
C. General Industry Pressure
In efforts to create various types of blood cells that are needed to treat a
multitude of blood diseases, researchers at Johns Hopkins University in
Maryland have patented processes for the separation of adult bone marrow
stem cells.' 52  Incidentally, these patents have already been subject to a
myriad of litigation, including that in Johns Hopkins University v. CellPro,
Inc. 53 Five years of litigation resulted in CellPro being required to pay
nearly $7 million in damages. 54  However, CeliPro contended that they
should not have to pay and that the infringement of the patents should not be
punished because of the high level of societal import associated with the
patents."' The court, nonetheless, did not follow CellPro's logic, but the
case did leave a rather perplexing legal idea that patent infringement could
be left unpunished if the value of the product being infringed upon was
thought to be significant enough. 56 Indeed, "[l]itigation resulting from such
a decision would certainly result in simultaneously clogging court dockets
and stifling research."' 57 Thus, it is almost certain that "[e]mbryo stem cell
151. Nat'l Inst. of Health, Stem Cells: Scientific Progress and Future Research Directions, Dept.
of Health and Human Services, ES-I (2001), available at http://www.nih.gov/news/stemcell/
scireport.htm.
152. Paegel, supra note 72, at 1191.
153. 152 F.3d 1342 (Fed. Cir. 1998).
154. Paegel, supra note 72, at 1197.
155. Id.
156. Id.
157. Id.; see also Peter Mikhail, Hopkins v. CellPro: An Illustration that Patenting and Exclusive
Licensing of Fundamental Science is Not Always in the Public Interest, 13 HARV. J.L. & TECH. 375,
381 (2000) (noting that governmental policies designed to promote technology transfer may indeed
be backfiring, causing licensees who have the potential to make life-sustaining discoveries millions
of dollars).
575
research promises to be fraught with litigation for many decades, as
companies and other countries such as Great Britain, Scotland, Holland,
France, and Japan vie for first rights, or, like CellPro, merely factor
infringement into part of the cost of doing business."' 58
D. General Responses
The ownership and control of biotech discoveries that is afforded with
the grant of a patent, is subject to great controversies ranging from:
disapproval of genetic modification technologies.... questioning of
the intent behind the legal strategies of biotech companies, debate
and political maneuvering over the social, ethical, legal and policy
implications of the use of some human biological materials, and
protests over the clinical protocols used for testing new biotech
products on human subjects.159
While some biotechnology companies fully support the intellectual
property protection of their inventions, mainly due to the economic
potential, "[a]ssorted groups have expressed concerns.., including groups
and individuals ranging from the National Conference of Catholic Bishops
and other clergy to anti-abortionist groups, bio-ethicists, scientists,
government officials, members of Congress, and patient advocate groups."'
' 60
Generally, "[e]thical concerns over stem cell research derive from what
bioethicists often speak of as the moral or special nature of the embryo.'
' 6
'
One of the primary concerns is over what should and should not be
158. Paegel, supra note 72, at 1197.
159. S. Van McCrary & Cheryl J.C. Erwin, Thinking Globally About Biotech Ethics: Is the Law
Enough?, 666 PRAG. L. INST. 983, 993-94 (2001) (noting the "ethical implications for the practicing
attorney who has a duty to make the client aware of all significant factors that may impact a decision
about legal strategy.").
160. Paegel, supra note 72, at 1186.
161. Casell, supra note 78, at 556 (explaining that "[tihe embryo has qualities of a living being
and a human being, but it is not a human life because it lacks neurological attributes that we ascribe
to humans in the special sense .... [it is] alive in a general sense, but it does not have cerebral
functions that give rise to consciousness."); see also Davis v. Davis, 842 S.W.2d 588, 597 (Tenn.
1992) (holding that embryos "are not, strictly speaking, either 'persons' or 'property,' but occupy an
interim category that entitles them to special respect because of their potential for human life."); see
also Kass v. Kass, 696 N.E.2d 174, 181 (N.Y. 1998) (holding that a divorced couple was obligated
to abide by a signed agreement which provided that if the Kasses no longer wished to initiate a
pregnancy, they would donate the frozen embryos for biological studies and research approved by
the clinic's in vitro fertilization program and thereby preventing Ms. Kass from being implanted
with an embryo when Mr. Kass did not want a child.); see also Casell, supra note 78, at 560
(reasoning that the courts in both Davis and Kass acknowledged the special nature of the embryo in
its usefulness for medical research as a preferred alternative to destruction as well as a dignity
inherent in the embryo that prefers the use of the embryos for implantation, or, if not, at least for a
noble purpose such as medical research).
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permitted a patent. 162 This position does not really address whether patents
based on biotechnology are good or bad; rather, it simply notes, "that we
must balance the incentive patents give to firms ... versus the cost.' 163
Another school of thought regarding the patenting of biotechnology is based
in more fundamentalist ideals and strongly discourages "patents on life."'164
This position is very political in nature while the concern over the balancing
of incentives is more policy-oriented.
165
While it remains unanswered how these issues will be resolved, they
will inevitably impact the direction that the patenting of biotechnological
intellectual property will take. 166 Indeed, it is important to note:
Biotechnology has fostered political debate since its inception.
Extremists on both sides fail to balance the values inherent in
biotechnology. In the European community, a spokesman for the
Social Democrat party contends that 'where human dignity is
affected, economic arguments do not count.' While such statements
represent an underlying truth about the moral dimensions of
biotechnology, they do not fully define the dimensions in this arena
any more than purely legal analysis exhausts the complexity of
162. Henry T. Greely, The Revolution in Human Genetics: Implications for Human Societies, 52
S.C. L. REv. 377, 388 (2001) (addressing the social consequences of the major developments in
human genetics).
163. Id.; see also Casell, supra note 78, at 563-64 (noting that:
[a]dherents of the middle position, that the embryo is something other than living or dead,
do not object to the destruction of unwanted embryos or to their use for scientific and
medical research. Indeed, the American Medical Association has stated that frozen
embryos may be donated, but not sold, to infertile couples or researchers, or may be
allowed to thaw and deteriorate. Acknowledging that the embryo is alive, but that its
special nature comes from the recombinant DNA within it, may be one step toward
appeasing stem cell research opponents. This argument rests on the fact that DNA is the
personifying feature of a 100-cell blastocyst, rather than the egg wall, cytoplasm, and
mitochondria, which are destroyed in stem cell derivation. [Human pluripotent stem
cells] derived from harvested embryos are directed to form cell lines, each of which
contains, in dormant form, the full component of embryonic DNA. The DNA has a
higher probability of existing for many years than the DNA of a frozen embryo, which
will most likely be discarded by an [in vitro fertilization] clinic. In this sense, the life
within the embryonic DNA lives on in the [human pluripotent stem cells] derived from
the embryo. (citations omitted).
164. Greely, supra note 162, at 388; see also David Tenenbaum, Finally. Generic Human Cells
Discovered, at http://whyfiles.news.wisc.edu/shorties/stem_cell.html (Nov. 20, 1998) (noting that
even greater controversy may result from stem cell research than from the well-known cloned sheep
"Dolly" in that "[w]ith Dolly, the clone of an adult sheep, at least researchers could reasonably know
what to expect when she grew up. In stem-cell work, no adult has been seen.").
165. Greely, supra note 162, at 388.
166. Id. (noting the importance of following these issues when it comes to the ramifications
associated with gene patents).
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issues. Enlightened biotechnology firms understand the potential
implications of ignoring public perception in the marketplace of
ideas. These implications include the negative economic
consequences to a company of a frightened public, or a public
convinced that the company has acted unethically or in a socially
irresponsible manner.' 1
67
It must therefore be recognized that "although ethical deliberations
initially coincide with legislative responses, ethical deliberations require
much more time to develop carefully and completely, and therefore continue
well beyond the advent of legislation."'
' 68
VI. FUTURE OF STEM CELL RESEARCH
A. General Advancement Potential
Generally, the ultimate hope among researchers and those in the
biotechnology community is to use embryonic stem cells as a "universal
donor cell" or an "in-stock item that could serve as raw material for new
liver cells ... or new spinal cord cells.' ' 169 Thus, the cells could potentially
be useful in the development of life-saving pharmaceuticals and inevitably
could have an extreme economic, sociological, and international impact.
B. Drug Development
One of the greatest potential benefits of embryonic stem cell research is
the possible benefit in drug development. Stem cell discoveries could
provide sources for testing new drugs and toxicological agents.170 That is,
specific cell types could be treated
with chemicals and measuring their response offers a short-cut to
sort out chemicals that can be used to treat the diseases that involve
those specific cell types. Ramped up stem cell technology would
permit the rapid screening of hundreds of thousands of chemicals
167. McCrary & Erwin, supra note 159, at 1013-14 (further noting that "[a]s recent psychological
and economic research makes clear, persons do not always evaluate risk in a purely rational manner.
Thus, the choice of a decision frame is an ethically significant act. This ethical dimension is
especially true in cases involving biotechnology.").
168. Knowles, supra note 81, at 16-17.
169. David Tenenbaum, Finally. Generic Human Cells Discovered, at http://whyfiles.news.wisc.
edu/shorties/stemcell.html (Nov. 20, 1998).
170. Paegel, supra note 72, at 1192.
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that must now be tested through much more time-consuming
processes. 171
Thus, "[t]ests could be conducted on stem cells instead of animals or
humans.' 72  This would essentially eliminate the need for human guinea
pigs as well as increase the speed at which results are obtained because stem
cells have the ability to divide much faster than normal cells in human and
animal test subjects. 73 Furthermore, drugs could be screened by testing
them on cultured human embryonic stem cells so as to lower the incidence
of drug-related birth defects. 174  Notably, it is believed that the results
obtained using stem cells could be more reliable than the conventional
testing that is currently available because it allows for increased benefits
while minimizing side effects.' 75
C. Therapeutic Potential
It is believed that embryonic stem cells could offer great benefits to the
general public by providing a means to gain a greater understanding of
genetically transmitted disease by tracking the cells differentiation
process.176 Until now,
[t]he earliest stages of human development have been difficult or
impossible to study. Human embryonic stem cells will offer
insights into developmental events that cannot be studied directly in
humans in utero or fully understood through the use of animal
models. Understanding the events that occur at the first stages of
development has potential clinical significance for preventing or
treating birth defects, infertility and pregnancy loss. A thorough
171. University of Wisconsin, Embryonic Stem Cell Fact Sheet, Office of News and Public
Affairs (Nov. 5, 1998), available at http://www.news.wisc.edu/thisweek/Research/Bio/Y98/
facts.html.
172. Paegel, supra note 72, at 1193.
173. Shirley J. Wright, Human Embryonic Stem-Cell Research: Science and Ethics, 87 AMERICAN
SCIENTIST 352, July 1, 1999, available at 1999 WL 3555448.
174. University of Wisconsin, Embryonic Stem Cell Fact Sheet, Office of News and Public
Affairs (Nov. 5, 1998), available at http://www.news.wisc.edu/thisweek/Research/Bio/Y98/
facts.html.
175. Paegel, supra note 72, at 1193.
176. Wright, supra note 173.
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knowledge of normal development could ultimately allow the
prevention or treatment of abnormal human development. 1
77
Additionally, embryonic stem cells may also be used to harvest tissue
that is genetically identical to a recipient patient, thereby reducing or
eliminating the potential for "rejection," the immunological response that
often serves as a severe complication following organ or tissue
transplants.77 Thus, the overall possible uses of embryonic stem cells are
vast and the potential benefits to the general public appear to be
unparalleled. Legal experts generally contend that United States patent law
has usually "worked well in providing incentives for scientific advances to
reach the public."' 79 Many in both the legal and scientific professions feel
that it will take time to resolve whether an adequate number and range of
cell lines are available to researchers. Regardless, all groups in the industry
seem to agree, that the primary concern should remain science benefiting the
public.
D. Economic Impact
Many people who are aware of the legal developments in the field of
biotechnology believe that "[t]he current judicial environment favors
protection of biotechnology research institutions and investors who look to
financial rewards for the enormous expense and risk involved in the making
of biotech products."' 80 Commercial success of biotechnology depends on
several factors. These factors include continued research, the ability to
attract necessary capital, and the time lapse between initiation of research
and approval of an applied product or process. As for the latter, one of the
greatest concerns in the industry is the growing backlog of patent
applications, particularly because the PTO is generally known for its
inconsistencies in patent approval.'
81
Stem cell research also holds great economic potential because
biotechnology and start-up companies want access to the lines. In fact, some
in the industry feel that President Bush's stem cell policy could actually
generate millions of dollars in new research and business. 182 Thus, many of
177. University of Wisconsin, Embryonic Stem Cell Fact Sheet, Office of News and Public
Affairs (Nov. 5, 1998), available at http://www.news.wisc.edu/thisweek/Research/Bio/Y98/
facts.html.
178. Knowles, supra note 81, at 14-15.
179. Rebecca Hoover, Stem Cell Debate Worth Study, Even Adjustment (Nov. 21, 2001), at 179.
Rebecca Hoover, Stem Cell Debate Worth Study, Even Adjustment (Nov. 21, 2001), at
http://www.heraldnet.com/Stories/01/8/22/14252291.cfm
180. McCrary & Erwin, supra note 159, at 1005.
181. Olsen, supra note 3, at 310.
182. Tortora, supra note 135 (noting the economic potential for Cincinnati, Ohio because it is
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those in a post-dot-corn troubled economy are hopeful that biotechnology
provides the spark that the United States economy currently needs.
Indeed, there is an enormous amount of money to be generated by
advances in stem cell technology not only in the medical industry, but in
agriculture as well. 83 However, there is a significant justifiable fear in the
struggling United States economy that if research is pushed overseas, the
United States will lose a valuable economic opportunity at a time when it is
needed the most. 184 Therefore, stem cell research, while it has the enormous
capability of increasing prosperity in the United States economy, could also
be very detrimental to the economy if pushed in the wrong direction.
E. International Developments
Despite the fact that the '806 patent may be challenged in court, its mere
existence could push stem cell research overseas.'85 One reason for this
arises from the idea that, if the over sixty cell lines allegedly supported by
President Bush's new regulations "match the description in the broadly
worded Wisconsin patent... their owners must obtain approval from the
foundation before distributing them."' 86  Additionally, scientists in other
countries may derive embryonic stem cell lines without the fear of
infringement that researchers in the United States face. 187 Along the same
lines, "companies in other countries are concerned that, if they distribute
their stem cells in the United States, the foundation might charge them with
patent infringement."' 88  Thus, many international companies are
manifesting the idea that, not only should they conduct their research abroad,
but they should keep it there and away from introduction in the United
States as well.
Such ramifications are already being felt. For example, ES Cell
International, a biotechnology company in Singapore, asserts that it has six
stem cell lines, but is not releasing any information until it further evaluates
home to several universities and hospitals that are currently researching adult stem cell
technologies).
183. See, e.g., Philip Cohen, Why would anyone in their right mind want to clone a baby when
animal cloning can go disastrously wrong? NEW SCIENTIST, May 19, 2001, at 14.
184. Tortora, supra note 135.
185. Stolberg, supra note 4, at Al.
186. Id.
187. Id.
188. Id. (reporting that "experts suggest that the Wisconsin patent is one reason researchers have
said little about many of the 60 stem cell lines that President Bush said exist around the world; the
owners of those cell lines are probably afraid to come forward.").
the lines to see if they fall within the scope of the '806 patent. 89 On the
other hand, BresaGen, Inc. in Athens, Georgia contends that the company
has developed four stem cell lines at a slightly later stage in embryo
development than those in the '806 patent held by the University of
Wisconsin.'" BresaGen further notes that it is being cautious so as to avoid
infringement claims of the '806 patent, but hopes to obtain its own separate
patent in the near future and will "make its four stem cell lines available to
researchers with no upfront cost provided the company receives the right of
first refusal for any resulting discovery having commercial potential."' 91
Other international developments in the field of stem cell research
include the goal of Dr. Ian Wilmut, the biotechnologist who cloned Dolly
the sheep at Scotland's Roslin Institute, to clone embryos to serve as the
source of stem cells. 192 In Great Britain, a prominent biotech company has
patented techniques for developing neural stem cells that may be used for
brain transplantation.' 93 Additionally, the French equivalent of the NIH has
been partially successful in treating patients inflicted with Huntington's
chorea by implanting fetal stem cells in their brains, while Japan is near the
final stages of approving guidelines for embryonic stem cell research.
94
A likely effect of withholding federal funding from private researchers
and companies is that "the private sector will continue using embryo stem
cells for research on [their] own, but the effect is likely to discourage and
slow progress. '"' 9 If the United States is absent from the race for embryonic
stem cell technology because of legal and political constraints, other
countries may immediately take a "position to reap the potentially enormous
economic benefits should they become successful with their research."' 9'
An extreme perspective on the possible consequences of this is that the
United States could become dependent on countries with stem cell
technologies to the degree that it relies on the Organization of Petroleum
Exporting Countries ("OPEC") for its oil.' 97
189. Id.
190. Agres, supra note 109, at 8.
191. Id. (explaining that this is a fairly common relationship between researchers and developers).
192. Robert Frank & Ralph T. King, Jr., Creator of Dolly Seeks Partners to Clone Embryos,
WALL ST. J., Jan. 21, 1999, at B6 (further indicating that the Roslin Institute has talked with Geron
Corporation as a potential commercial partner to help aid in the institute's research efforts).
193. Emerging Applications in Human Stem Cell Therapy, CHEM. BUS. NEWSBASE (Apr. 5,
2000), available at 193.Emerging Applications in Human Stem Cell Therapy, CHEM. BUS.
NEwsBASE (Apr. 5, 2000), available at 2000 WL 17082990.
194. Paegel, supra note 72, at 1194-95.
195. Id. at 1201.
196. Id. at 1201-02.
197. Id. at 1202.
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VII. GENERAL CONSIDERATIONS AND RECOMMENDATIONS
A. Considerations
Generally, "scientific experimentation most often precedes the
announcement of the discovery or innovation by many years. ' 98 Although
it has traditionally been that "the announcement of a scientific development
takes place in a scientific publication, recent increases in industrial funding
for scientific innovation has resulted in these announcements increasingly
being made in newspapers."' 99  Since new scientific techniques or
applications that take years to develop, especially in the field of
biotechnology "often spark public reaction and prompt legal and ethical
analysis and discussion," upon public announcement, spontaneous public
policy and ethical discourse often "begin[s] much too late," and "develops
more slowly."200 Thus, "[c]areful science develops over a long period of
time, but once a development is announced, public reaction follows swiftly,
and in many cases, pressure mounts to quickly introduce a legislative
response."' ' Isolated analysis and decision-making of an issue, particularly
a biotechnological issue, often results in "laws [that] may be drafted too
vaguely, broadly, or narrowly so as to inhibit the development of scientific
innovation."
20 2
Illustrative of the seemingly ad hoc legislation adopted in response to
untimely public reaction is the initial legislation that occurred during former
President Clinton's administration in response to public concerns over the
use of federal funding to support embryonic stem cell research.20 3 When the
general public first became informed that embryonic stem cells were being
cultured, public and political reaction on one side soon demanded that laws
198. Knowles, supra note 81, at 15.
199. Id.
200. Id. at 15-16 (noting that "while science progresses behind metaphorically closed doors, little
or no discussion of policy or regulation intersects with this process. Hence, those engaged in public
policy and ethical discourse must struggle to understand the new science or technology, as well as
the implications of these scientific developments for society.").
201. Id. at 16.
202. Id. at 20 (remarking that President Clinton's announcement that federal funds were not to be
used for human cloning was only meant to cover reproductive cloning, but on its surface appeared to
pertain to therapeutic cloning as well, all at a time when embryonic stem cell research would soon
turn out enormous technological advances).
203. Id. at 17. When the public became aware of the issue of reproductive human cloning, even
before the National Bioethics Advisory Commission could complete its advisory report, several bills
had already been presented to Congress in support of a ban on human cloning, and President Clinton
declared that federal funding would not be permitted to support human cloning. Id.
restrict federal funding of the research, while the other side called for
funding expansion.2 °4 The National Bioethics Advisory Commission, after
being commissioned by President Clinton, eventually completed a report on
the ethical implications raised by embryonic stem cell research, indicating
that the then existing ban on the use of federal funds for embryonic research
should be eliminated so as to allow the use of embryonic stem cells in
research.205 However, by the time this report was released, President Clinton
had already announced that federal funding would not be available to
support embryo research to isolate stem cells. 20 6  Thus, before the
ramifications of the research could be fully assessed, legislation, in direct
response to public outcries, was already underway.0 7
Additionally, when determining whether an incidence of infringement
exists, it is important that a patent is evaluated in the proper time frame.20 8
There should be an evaluation of the patent within the proper time frame
because "standards for patentability and disclosure center[s] on the level of
skill in the art at the time of patent application filing.' ,20 9 Therefore, "[a]s
biotechnology matures, an otherwise unpredictable art," such as embryonic
stem cell technology, "can become more predictable and thus might permit
increasingly broader claims based on limited examples. 210  Such
consideration is of great importance when making an effective assessment of
the social, political, and economic impact that changes to current patent laws
may bring. This is especially true given that universities and/or companies
that object to the manner by which WARF is handling its patent rights could
look to the courts for remedies.21' While experts are generally divided on
whether or not WARF's patents would hold up if challenged in court, some
experts admit that the patents in question, which "cover stem cells in any
primate, from monkey to man," are very broad, and "[g]enerally speaking,
broad patents in the biotechnology area tend to be vulnerable. 2t 2
204. Id. at 17-20. Unlike the United States, in 1984 the United Kingdom issued the Warnock
Report on the ramifications of assisted reproductive technologies which included a broad mandate
promoting the continued pursuit of knowledge and identifying potential areas of ethical and public
concern so as to create a broad regulatory framework that would allow for flexibility around issues
that were to be specifically addressed when they arose. Id.
205. Id. at 17-18.
206. Id. at 17.
207. Id. at 18.
208. Sung, supra note 34, at 197.
209. Id. at 197-98 (noting that "appreciation of this temporal distortion is particularly important
where the issue involves whether the patent disclosure of a specific species supports the scope of
broad genus claims.").
210. Id
211. Gertzen, supra note 130.
212. Id. (discussing Arti K. Rai, a University of Pennsylvania law professor who has been
following stem cell research very closely).
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In April 1998, Stuart Newman and Jeremy Rifkin, president of the
Foundation of Economic Trends and a biotechnology activist, filed a United
States patent application for a chimera, or a bio-engineered human-animal
hybrid.213 The applicants admitted that the application was filed
not to obtain exclusive rights for further development and
commercialization of the technology . On the contrary, the
application was filed with the parallel intentions of forcing a policy
stand on the part of Congress and the PTO regarding the
patentability of human material, and to hinder further development
of the technology.
14
Rather unsurprisingly, the PTO issued a statement noting that it was
prepared to reject the application, or those of its kind, based on "public
policy and morality." '215 While this announcement was in accord with the
position taken by the PTO in 1987 when it declared that "a claim directed to
or including within its scope a human being will not be considered to be
patentable subject matter, '1216 the PTO failed to define where the line was to
be drawn. 2 17 That is, despite the 1987 statement, "[t]he PTO has not adopted
a policy of excluding all patents involving human materials." 2tt  In fact,
patents have been granted to cover transgenic animals, or those animals that
have had one or more human genes incorporated into their genetic sequence
for the purpose of encoding human proteins.219  It is this type of
inconsistency and lack of clarity in existing patent laws that creates
213. Jagels, supra note 53, at 116; see also Carole B. Fehilly, Interspecific Chimaerism Between
Sheep and Goat, 307 NATURE 634 (1984) (stating generally that a chimera is an organism composed
of heterogeneous cells that are created by combining embryonic cells from two or more species).
214. Jagels, supra note 53, at 116 (citing Jenna Green, He's Not Just Monkeying Around, 22
LEGAL TIMES, SI 7 (1999). The beauty of the strategy was, that if the PTO rejected the application,
the policy underlying the rejection would discourage further development. Id. On the other hand, if
the patent was issued, Newman and Rifkin would retain the rights to develop the invention,
removing commercial incentives for other parties to pursue the technology. Id.
215. U.S. Patent and Trademark Office Media Advisory, No. 98-6, Facts on Patenting Life Forms
Having a Relationship to Humans, (April 1, 1998), at http://www.uspto.gov/web/offices/com/
speeches/98-06.htm; see also Jagels, supra note 53, at 138 (reasoning that because the Patent Act
"does not specifically require moral balancing, and because social concepts of morality are in a
continuous flux, courts have rightfully been reluctant to use the morality doctrine as the sole basis
for rejecting patent applications.").
216. Commissioner of Patents and Trademarks, Policy Statement on Patentability of Animals,
1077 OFF. GAZ. PAT. OFFICE 24 (1987), reprinted in DONALD S. CHISUM, CHISUM ON PATENTS,
app. 24-2 (1999).
217. Jagels, supra note 53, at 117.
218. Id.
219. Id.
confusion and promotes legitimate scientific, economic, political and ethical
concerns, such as those currently being expressed in the area of embryonic
stem cell research.22 °
B. Recommendations
The primary "goal of United States patent law is to '[p]romote the
progress of [s]cience and [u]seful [a]rts,' not to set social policy., 221 It is
almost undeniable that something, at some level in the scientific, political,
ethical, and legislative processes needs to change or be altered.222 One such
change is "the need for increased transparency and dialogue between
scientists, ethicists, and policy makers," throughout.223  The United States
should attain,
a more comprehensive understanding of new developments and
draft laws that reflect that understanding. It is possible to develop a
broadly framed legislative mandate and to structure regulatory
bodies that are responsive to change. In so doing, we could use the
law to promote flexibility and continued conversation regarding the
issues involved, and to make transparent the ethical commitments
implicit in our governing policies.224
As a result, "[w]e must, for example, ask where [embryonic stem cell]
technology fits in embryo research; how it may pose problems for our
human subjects research guidelines; and even how we can design a
comprehensive regulatory system," based on these projections." 5
There also needs to be an increase in the amount of integration that
exists between international and domestic scientists, ethicists, and
legislators. 6 Since embryonic stem cell research is an issue that affects
220. See, e.g., Knowles, supra note 81, at 17-18.
221. Jagels, supra note 53, at 146-47 (citing U.S. CONST. art I, § 8, cl. 8.).
222. See, e.g., Rebecca Hover, Stem Cell Debate Worth Study, Even Adjustment (Aug. 22, 2001),
at http://www.heraldnet.com/Stories/01/8/22/14252291.cfm (indicating that in light of President
Bush's new policy on stem cell research, both Republican and Democratic lawmakers are already
looking at the possibility that patent laws will have to be revised to ensure the ability of scientists to
develop and distribute possible medical advances); see also United Press International, Stem Cell
Research Called Revolutionary (1999), at http://cigna.syndication.thehealthnetwork.com/lnHealth/
newsbasicdisplay.asp?docid=417&a (noting that Todd Dickinson, Patents and Trademarks
Commissioner, suggests that since stem cell research is extremely expensive and requires a large
amount of time for commercial development, "federal patent laws need to be changed to give the
biotechnology industry greater patent protection so its researchers can attract more investment.").
223. Knowles, supra note 81, at 18.
224. Id. at 20.
225. Id. at 21.
226. Id. at 21; see also Cynthia M. Ho, Splicing Morality and Patent Law: Issues Arising From
Mixing Mice and Men, 2 WASH. U. J.L. & POL'y 247, 285 (2000) (reasoning that "[e]ven if ethics
were to be incorporated in the United States' patent laws, further study of the purpose of such an
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everyone both globally and personally, isolated examination of the research
and its ramifications may "result in recommendations for oversight.
227
Therefore, increased integration and cooperation between scientists of all
nations will allow them to uncover strengths and weaknesses at a more rapid
pace, which inevitably results in a beneficial situation for everyone on a
global scale.
Additionally, under recent embryonic stem cell research regulations,
various regulatory agencies oversee scientific applications. Gene transfer
issues are the responsibility of the recombinant DNA advisory committee,
while the Food and Drug Administration avers that it has the capability to
regulate human cloning mechanisms under the Public Health Service Act
and the Federal Food, Drug, and Cosmetic Act.2 8 These are essentially
isolated regulatory systems that operate independently of one another,
resulting in a central weakness that inhibits the formation of "a
comprehensive picture of the state of the science at any given time.2 2 9
One way to change the impact that intellectual property protection has
on embryonic stem cell research is to actually change that which the PTO
presently determines to be patentable. Ironically, the 2001 Utility
Guidelines suggest that the PTO has changed its position on patentability,
particularly in the field of biotechnology.23 ' By requiring that a claimed
invention have a "substantial, specific, and credible utility," these new utility
guidelines, if appropriately applied, may restrict inventors from seeking
patent protection for findings based upon speculation so that subsequent
research and development may be controlled.232 That is, "requiring an
inventor to assert a specific, substantial, and credible utility may prevent
'shotgun' [inventors] who assert only speculative utility ... from obtaining
patent protection.' 2 3  Thus, one way to limit the amount of control that
exclusion, as well as how that impacts the patent system, would have to be considered.").
227. Knowles, supra note 81, at 20.
228. Id. at 19; see also Establishment and Listing for Manufacturers of Human Cellular and
Tissue-Based Products, 63 Fed. Reg. 26,744 (May 14, 1998) (to be codified at 21 CFR pts. 207, 807,
and 1271) (setting forth the proposition that the Public Health Service Act, 42 U.S.C. § 262 (1994),
enables the Food and Drug Administration to regulate human cellular and tissue products).
229. Knowles, supra note 81, at 19.
230. See, e.g., Olsen, supra note 3, at 298.
231. Worrall, supra note 58, at 131-32.
232. Id. at 135.
233. Id. at 134-5 (explaining that the 2001 Utility Guidelines could prevent inventors from
claiming uncharacterized DNA sequences that discourage subsequent research and development,
hindering the inventors' ability to obtain broad patent rights over DNA compositions that will give
the patent holder excessive control over therapeutic developments related to the gene product which,
at the time of patenting, may only be a speculative utility for a putative protein); see Jagels, supra
note 53, at 145 (noting that "[a] stronger utility requirement would not only limit patents based on
organizations like WARF and Geron hold over the embryonic stem cell field
is to promote this suggested requirement that a higher level of utility be
established before patent protection can be granted on embryonic stem cell
lines and their derivatives.
Additionally, when propositioned for patent protection by inventors of
other embryonic stem cell lines, the PTO, rather than asserting that stem cell
lines with homology to known stem cell lines have well-established utility,
should consider whether the utility of the new stem cell line meets the
specific and substantial utility requirement. 234  Since slight differences in
stem cell lines can cause extremely significant differences in biological
activity and great variations in functionality, homology should be thought of
as a very limited predictor of actual function by those skilled in the art.23 5
Thus, the PTO should recognize the extreme "limitations of [the] homology
arguments," because failing to do so "risks granting patents that the courts
may subsequently invalidate for lack of utility. 2
36
An immediate measure that may be taken to ensure that scientists have
adequate access to the embryonic stem cell line covered by the WARF '806
patent would be the forced licensing of the patent.237 Notably, "[w]ithin a
system where universities have title to patents sponsored by government-
funded research, we must ask whether the way universities license these
patents comports with the public interest., 238  For instance, the federal
government could require that WARF and Geron exploit the patent to its
fullest by allowing scientists to fully access the technology at minimal or no
questionable motives (such as the Newman application), but would also keep in check the patenting
of newly discovered genes and processes until a clearly defined function or use can be established.").
234. Jagels, supra note 53, at 142 (noting that "[i]nstead of asserting that sequences with
homology to known sequences have well-established utility, the PTO should consider whether the
utility of the claimed sequence establishes the threshold specific and substantial practical utility
required by the courts.").
235. Id. at 142-43 (reasoning that although proteins of similar sequences often have similar
functions, small differences in the sequences of other proteins may result in an extremely different
functionality, thereby diminishing the reliance that should be placed on a homology argument when
assessing the utility of a sequence); see also Steven E. Brenner et al., Assessing Sequence
Comparison Methods with Reliable Structurally Identified Distant Evolutionary Relationships, 95
PROCEEDINGS OF THE NAT'L ACAD. OF SCI. 6073 (1997).
236. Worrall, supra note 58, at 143.
237. See Johns Hopkins Univ. v. CellPro, Inc., 152 F.3d 1342, 1357-62 (Fed. Cir. 1998) (holding
that CellPro, a biotechnology company that had received federal approval for the process of isolating
and separating stem cells, had infringed patents claiming purified suspensions of stem cells and
monoclonal antibodies used to produce such suspensions); see also Mikhail, supra note 157, at 381
(explaining that "[w]hile encouraging the private sector to develop federally funded basic research is
an important goal, Hopkins v. CellPro illustrates that allowing a university to patent, hold title, and
maintain unlimited control of the results is not without its shortcomings.").
238. Mikhail, supra note 157, at 381 (noting that the passage of the Bayh-Dole Act in 1980 was
aimed at allowing universities to patent and hold title to inventions developed with government
funding with the goal that the patent system would promote the utilization of inventions that resulted
from federally funded research and development).
588
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cost.239 Such measures would indeed remedy at least part of the concern by
scientists and biotechnology companies that they are not able to use the stem
cell lines and corresponding technology for which they may receive the
much needed federal funding.
Additionally, revisions to President Bush's 2001 stem cell policy may
be necessary. For example, there is concern that the policy is too limited on
the number of lines that may receive funding for research and the mere
existence of these lines.240 While "it will take time for the NIH to resolve
scientific questions about whether an adequate number and range of stem
cell lines exist ... the president ought to consider more flexibility in his
policy."1
241
VIII. CONCLUSION
It is nearly undeniable that advances in stem cell research have the
potential to change the nature of human society forever. However, while
these developments could serve to "cure or prevent human suffering," it
should be noted that "they also give us a greater ability to inflict such
suffering. 242 Thus, it is extremely evident that at some point in the process
that allows for the patent protection of technologies or key components of
technologies that could shape the future of human existence, a change
inevitably needs to be made. When addressing this, however, both
lawmakers and ethicists alike need to take note of the depth of the issue at
hand and to recognize the long-term ramifications of their decisions.
Therefore, any decisions concerning the future of embryonic stem cell
research and its associated technologies should be made considering a broad
239. See, e.g., North American Free Trade Agreement, entered into force Jan. 1, 1994, U.S.-Can.-
Mex., 32 I.L.M. at 605 art. 1709(8) (explaining that the North American Free Trade Agreement
establishes the minimum requirements the three countries must offer within their respective
territories to the nationals of each of the other two countries in order to mandate that there is
adequate and effective protection and enforcement of intellectual property rights, while further
ensuring that the measures to enforce such rights do not become barriers to trade); see also Ryan H.
Flax, 5 NAFTA L. & Bus. REV. AM. 461, 474 (1999) (prior to the North American Free Trade
Agreement, the United States had no laws mandating that patent holders "exploit their patents in a
particular country, with failure to do so resulting in forced licensing," while Mexico did "permit the
granting of compulsory licenses for failure to exploit unless the patent holder" was importing a
patented product or products made by a patented process).
240. See, e.g., Agres supra note 109, at 8 (noting that there are allegedly sixty stem cell lines that
are currently approved for federally funded research under President Bush's policy).
241. Rebecca Hoover, Stem Cell Debate Worth Study, Even Adjustment (Aug. 22, 2001), at
http://www.heraldnet.com/Stories/01/8/22/14252291.cfm.
242. Greely, supra note 162, at 390.
time frame, with extreme scrutiny, and of utmost importance, with a great
amount of care, because, indeed, there is no telling the places we'll go.
Stacy Kincaid
